Boofamons
12-05-2022, 02:47 AM
In one such trial, comparing the pegylated liposomal doxorubicin to topotecan, the subset of patients who were platinum sensitive had better outcomes with either drug and in particular with pegylated liposomal doxorubicin relative to the platinum resistant cohort ivermectin over the counter ([Only registered and activated users can see links]) Interestingly, according to data presented in Hart et al